Know Cancer

forgot password

Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma

Phase 1/Phase 2
18 Years
Not Enrolling
Metastatic Melanoma

Thank you

Trial Information

Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma

Inclusion Criteria:

- Patients with unresectable or metastatic melanoma, for whom treatment with Ipilimumab
is indicated

- Radiologically measurable disease by immune-related Response Criteria

- ECOG performance status of 0-1.

- Anticipated lifespan greater than 12 weeks.

- At the time of day 1 of the study, patients must be at least 3 weeks since surgery

- At the time of day 1 of the study, patients with brain metastases must be
asymptomatic and, at least 8 weeks without tumor progression after any whole brain
radiotherapy, at least 4 weeks since craniotomy and resection or stereotactic
radiosurgery, at least 3 weeks without new brain metastases as evidenced by MRI/CT

- The following laboratory parameters must be within the ranges specified: Hemoglobin-≥
9 g/dL, WBC-≥ 3.0 x 109/L, INR-≤ 1.5, Total Bilirubin-≤ 1.9 g/dL & AST/ALT-≤ 3 x ULN

- Have been informed of other treatment options.

- At least 18 years. Able and willing to give valid written informed consent.

Exclusion Criteria:

- Any contraindications for ipilimumab/Yervoy®.

- Prior exposure to ipilimumab/Yervoy®

- Prior exposure to Anti-OX40 or a mouse monoclonal antibody.

- History of severe allergic reactions to any unknown allergens or anti-OX40 Autoimmune
disease except for autoimmune thyroiditis or vitiligo.

- Unresolved immune related adverse events following prior biological therapy.

- Metastatic disease to the central nervous system for which other therapeutic options,
including radiotherapy, may be available.

- Known immunodeficiency or HIV, Hepatitis B or Hepatitis C positivity.

- Other serious illnesses (e.g., serious infections requiring antibiotics).

- Participation in any other clinical trial involving another investigational agent
within 4 weeks prior to day 1 of the study.

- Mental impairment that may compromise the ability to give informed consent and comply
with the requirements of the study.

- Lack of availability for immunological and clinical follow-up assessments.

- Women who are breast feeding or pregnant as evidenced by positive serum pregnancy
test (minimum sensitivity 25 IU/L or equivalent units of HCG) done within 72 hours of
first dosing.

- Women of childbearing potential not using a medically acceptable means of
contraception for the duration of the study.

- Any condition that, in the clinical judgment of the treating physician, is likely to
prevent the patient from complying with any aspect of the protocol or that may put
the patient at unacceptable risk.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Assess safety and tolerability according to the National Cancer Institute CTCAE v4.0 (Phase 1 and 2)

Outcome Description:

Laboratory tests, vital sign measurements, physical exams and patient interviews will be performed to detect new abnormalities and deteriorations of any pre-existing conditions

Outcome Time Frame:

Up to 16 weeks

Safety Issue:


Principal Investigator

Jedd Wolchok, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

October 2012

Completion Date:

August 2014

Related Keywords:

  • Metastatic Melanoma
  • OX40
  • Anti-OX40
  • Ipilimumab
  • Melanoma
  • Melanoma



Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
Providence Portland Medical CenterPortland, Oregon  97213-3635